Canada: Pharmacapsules @ Gowlings – July, 2007

Last Updated: July 19 2007

Edited by Jennifer Wilkie and Chantal Saunders

  • Eli Lilly Canada and PMPRB Reach Agreement on the Price of Forteo
  • Guidance Re Scope of and Implementation of the Data Protection Regulations
  • Stem Cell Patents Challenged
  • U.S. FDA Finds Consumers Continue to Buy Potentially Dangerous Drugs Over the Internet
  • Europeans and Americans Will Now Share More Information About Food Safety
  • Recent Cases
Eli Lilly Canada and PMPRB Reach Agreement on the Price of Forteo

By Wayne Critchley

In an announcement released July 6, 2007, the PMPRB reported that it has approved a Voluntary Compliance Undertaking by Eli Lilly Canada with respect to Forteo.

Forteo (teriparatide) was introduced by Lilly Canada in July 2004. It is a recombinant human parathyroid hormone and is the first in a new class of bone formation agents. It is indicated for the treatment of certain cases of severe osteoporosis in patients who have failed or are intolerant to previous osteoporosis therapy.

For price review purposes, the PMPRB did not identify any comparator drugs to Forteo and therefore reviewed the price with reference to international prices. It concluded that, at the time of introduction, the price in Canada exceeded the median of international prices by approximately 12%. As a result, the PMPRB alleges that Eli Lilly received excess revenues from the sale of Forteo during 2004 and 2005, but by 2006, the price was within the PMPRB's guidelines.

For purposes of resolving this matter, Lilly Canada has agreed on the maximum non-excessive (MNE) prices identified by the Board and will take action to offset the remaining excess revenues of approximately $333,000.00. This sum will be offset by maintaining the price of Forteo in 2007 at levels below the MNE price calculated by the Board.

In making the undertaking, Lilly Canada makes no admission that the price of Forteo in Canada is now or was excessive for purposes of the Patent Act .

For more information, please see:

For a copy of the Voluntary Compliance Undertaking, please see:

Guidance Re Scope of and Implementation of the Data Protection Regulations

By: Jennifer Wilkie

On June 25, 2007, TPD released a draft guidance document relating to the Data Protection Regulations which came into force last October. The draft guidance document speaks to, inter alia , the scope of data protection, requirements for marketing, the Register of Innovative Drugs, terms of protection, how the Minister will implement decisions with respect to providing data protection or not, and pediatric data protection.

Comments on the draft guidance are being sought by September 17, 2007.

To review the draft guidance document, please see:


Stem Cell Patents Challenged

By: John Norman

Earlier this year ,the U.S. Patent and Trademark Office ("USPTO") released a preliminary decision indicating that patents covering human embryonic stem cells are not inventive and that it may throw them out. The owner of the patents fired back indicating that the patents should be upheld because the inventor was the first to successfully isolate embryonic stems when others had failed.

Recently, however, several internationally recognized stem-cell researchers have jumped into the fray and filed documents with the USPTO alleging that the work leading to the patents was not inventive. Instead, the documents allege that the inventor was the first to isolate embryonic stem cells because he had access to high quality embryos and adequate research funding.

For more information, please see:

U.S. FDA Finds Consumers Continue to Buy Potentially Dangerous Drugs Over the Internet

By: Natalie de Paulsen

On July 2, 2007, the FDA again warned consumers about the dangers of buying medications over the Internet. The FDA highlighted the following safety concerns raised by the purchase of drugs from unregulated Internet sites:

  • use may require careful dosing and monitoring;
  • purchased drugs may not have adequate labelling for safe use;
  • purchased drugs may have been withdrawn from the U.S. market for safety or efficacy reasons; and
  • purchased drugs may expose the consumer to significant drug\drug interactions.

The FDA also discussed new data which indicates that for 45% of the drugs imported through foreign mail, and potentially purchased by consumers on unregulated Internet sites, there are low cost generic versions available in the U.S. This finding may suggest that, in addition to attempting to save money on drug purchases, some consumers may also be buying foreign drugs to avoid obtaining a prescription. Some of the products that have been intercepted which are available as generic products in the U.S. include amoxicillin tablets, fluoxetine capsules, paroxetine tablets and warfarin tablets.

For more information, please see:

Europeans and Americans Will Now Share More Information About Food Safety

By: Natalie Rizkalla-Kamel

In an effort to end the conflict between Europeans and Americans over issues concerning cloned and genetically modified food, the U.S. FDA and the European Food Safety Authority signed an agreement to share more information about the safety of food supply. The FDA says this agreement will pave the way for formally sharing confidential scientific information and that it will help protect confidential information under both regions' laws.

For more information, please see:

Recent Cases

By: Beverley Moore

Canada v. Janssen-Ortho; Appeal of Decision on ATI Request; June 26, 2006 - cisapride

The drug company was required to give thousands of pages of documents to the Minister of Health (the Minister) when one of its products was withdrawn due to safety concerns. An Access to Information (ATI) request was made for these documents, and the Minister wished to disclose many of them. The drug company resisted.

Before the Federal Court, the Minister argued that some of the documents said to be confidential were not because they comprised submissions made based on public documents. The Court held that the submissions were confidential, and the fact that the drug company may have relied upon public information was not public knowledge. The Court also held that release of the identity of employees of the drug company was not proper as there was not consent to the release of their names. The Minister appealed this decision.

The Court of Appeal dismissed the Minister's Appeal with costs. The Trial Judge's decision related to questions of mixed fact and law, and could not be overturned without palpable and overriding error. No such error was found.

The full text of the decision can be found at:

Ranbaxy v. Pfizer; Appeal of Interlocutory Motion in 55.2; June 20, 2007

At the trial division, the innovator succeeded in a motion to amend its Notice of Application for a second time, as its initial amendments had been based on misleading information from the generic company.

The Court of Appeal affirmed the decision of the Motions Judge. If the generic company had not given the innovator erroneous information, the innovator would not have amended its original application to discontinue proceedings relating to two patents. Thus, the amendments simply place the innovator in the position in which it would have been but for the misleading information.

Furthermore, the Order extending the statutory stay was discretionary and justified on the record before the Court.

The full text of the decision can be found at:

Apotex v. AB Hassle; Appeal Motion to Dismiss Impeachment Proceeding; June 27, 2007; omeprazole

The two companies litigated this patent in proceedings under the PMNOC Regulations . The Federal Court issued an Order prohibiting the Minister from issuing a NOC until the patent expired. The Court of Appeal upheld the Order and the Supreme Court did not grant leave to appeal.

The generic company then sued to impeach the patent at issue. The patent expired in January 2007. The patentee then brought this motion to dismiss the proceeding as an abuse of process.

The Prothonotary dismissed the motion. The Federal Court dismissed the appeal. One of the remedies sought by the generic company, if it succeeds, is a declaration that it is entitled to s. 8 damages from the prohibition proceedings. The Court held that as it is not plain and obvious that a determination of this proceeding will not have legal consequences on the parties, the proceeding cannot be dismissed.

The full text of the decision can be found at:

AB Hassle v. Apotex; 55.2 Proceeding; June 28, 2007 – omeprazole

The Federal Court dismissed the application for prohibition on the basis that the patent is invalid on the grounds of anticipation and obviousness. The Court also found that the claims relied upon do not contain any therapeutic aspects and are ineligible for inclusion on the Patent Register.

The generic company, in earlier proceedings, alleged non-infringement of the patents at issue. It did not challenge validity, and succeeded on narrow points of non-infringement. Then, the generic company sent the within NOA, alleging new grounds of non-infringement and invalidity. The Court held that despite the incremental challenges of the generic company, the innovator cannot use its own unmeritorious challenge as the foundation for an abuse of process argument alleging juridical inefficiency. As the generic company was not attempting to split its case, or avoid an earlier unfavourable disposition, subsequent litigation could be permitted.

The full text of the decision can be found at:

Novopharm v. Abbott; Appeal of 55.2 Proceeding; June 28, 2007; lansoprazole

The Federal Court of Appeal dismissed the generic company's appeal of a decision granting prohibition.

The generic company had alleged non-infringement in its NOA. The trial judge found that the generic company's bottle label and product monograph will induce and encourage physicians to prescribe the medicine for an infringing use. The Court of Appeal refused to disturb those findings without palpable and overriding error.

The Court dismissed Novopharm's argument the recent Supreme Court decision in Astrazeneca was determinative of the issues. Novopharm had not raised the issue of whether it had to address the patents in its NOA. Thus, the judge did not err in not considering the argument.

The full text of the decision can be found at:

Apotex v. Bayer; Appeal of 55.2 proceeding; June 22, 2007 – ciprofloxacin

The Federal Court of Appeal dismissed the generic company's appeal of a decision granting prohibition. The patent had expired, and subsequently a NOC issued before the appeal was heard, thus the appeal was moot. However, the Court allowed the appeal to continue because its outcome could affect the rights of the generic company under s. 8 of the PMNOC Regulations .

The Court undertook a determination de novo , of a question of obviousness not considered by the trial judge. The Court accepted the evidence of the innovator as persuasive on the issue, and found the patent not to be invalid on the basis of obviousness. The Court did hold that the trial judge gave undue weight to the commercial success and utility of the medicine on the issue of obviousness. However, the issue was not consequential.

The full text of the decision can be found at:

Pfizer v. Apotex; 55.2 proceeding; June 15, 2007 – quinapril

The Court dismissed an application for prohibition. The generic company alleged non-infringement and included an Undertaking that it would not engage in the infringing use.

The innovator company does not have approval to sell the medicine for the patented use.

The Court found that the undertaking signed by the CEO was binding on the company. The Court further held that any NOC issued shall contain a condition consistent with the Undertaking in the NOA.

The full text of the decision can be found at:

Pfizer v. Ranbaxy; Appeal of motion to dismiss 55.2 Proceeding, s. 6(5); June 18, 2007 – atorvastatin

The generic company brought a motion to dismiss the proceeding as an abuse of process. The Prothonotary dismissed the motion. The Federal Court upheld the decision.

The generic company has two processes to make its medicine. One process infringes, yet the other process, which is alleged in the NOA and submitted to Health Canada, does not. The generic company argued that the only process to be considered is that submitted to Health Canada. The Court found that the generic company had not met its burden that it is plain and obvious and the application cannot succeed.

The full text of the decision can be found at:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.